Home / Pharma News

Pharma News

Lannett to co-develop biosimilar insulin product with Chinese partner

US generics maker Lannett Company (Lannett) announced on 22 April 2016 plans to co-develop a biosimilar insulin product for the US market with its strategic partner in China, Yichang HEC Changjiang Pharmaceutical (Yichang), which is part of the HEC Group.

Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical Company (Takeda) have formed a joint company ‘Teva Takeda Yakuhin’ to produce and sell off-patented medicines in Japan.

SGS and DiscoverX to collaborate on bioassays for biosimilars

Contract solutions provider SGS announced on 30 March 2016 that it had entered into a collaboration with innovative life science company DiscoverX.

Dr Reddy’s and TRPharm collaborate on biosimilars in Turkey

Generics giant Dr Reddy’s Laboratories and Turkish pharma start-up firm TRPharm announced on 10 March 2016 that they had entered into a strategic collaboration agreement for a portfolio of biosimilars in Turkey.

Partnership between PlantForm and Guelph University for biosimilar trastuzumab

Canada-based PlantForm Corporation (PlantForm) announced on 3 March 2016 that it had been awarded a Collaborative Research and Development Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC).

Oncobiologics and Premier make biosimilars deal

US biotechnology company Oncobiologics and healthcare performance improvement alliance Premier announced on 3 March 2016 that they had entered into a collaboration aimed at increasing the use of biosimilars.

Strides Shasun acquires Australian and Kenyan generics makers

India-based generics manufacturer Strides Shasun has increased its generics portfolio and presence across the globe with two new acquisitions.

Mylan to acquire Swedish drugmaker Meda

US generics manufacturer Mylan announced on 10 February 2016 that it had made a deal worth US$9.9 billion (for shares and debt) to buy Swedish drugmaker Meda.

Fuji Pharma gains rights to darbepoetin alfa biosimilar in Japan

Japan-based Fuji Pharma announced on 5 January 2016 that it had signed a license agreement with Chong Kun Dang Pharmaceutical (CKD Pharma). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of CKD Pharma’s darbepoetin alfa biosimilar (CKD‑11101).

Mylan and Momenta to jointly develop and commercialize six biosimilar products

Mylan NV has agreed an exclusive global collaboration with Momenta Pharmaceuticals Inc (Momenta) to develop, manufacture and commercialize six of Momenta's biosimilar candidates.